A Phase 1 clinical trial using chimeric antigen receptor (CAR) T-cell therapy for pleural mesothelioma tumors shows promise for patients.
New type of immunogene therapy, also called virotherapy, is the subject of a Phase 3 clinical trial for patients with pleural mesothelioma.
The European Thoracic Oncology Platform (ETOP) recently completed a disappointing phase 3 trial for mesothelioma treatment.
Phase II of a clinical trial is recruiting mesothelioma patients to test the effectiveness of two immunotherapy medications in combination.
In August, the Centers for Medicare & Medicaid Services (CMS) approved the use of CAR T-cell therapy in patients with two specific cancers.
Results of a recent Phase 3 clinical trial lead researchers to believe immunotherapy drug Ofev is ineffective. Here are the details.